PS 58 The challenges of insulin therapy in type 2 diabetes PS 57 Insulin therapy: fast acting insulin analogues PS 56 Insulin therapy: real world studies PS 53 Key issues in improving outcomes in people with diabetes, education and costs PS 52 Novel glucose-lowering agents in type 2 diabetes PS 51 Novel agents to treat diabetes and its consequences PS 50 Oral therapies: metformin, sensitizers and other non-secretagogues PS 49 Various aspects of nutrition and diet PS 48 Various clinical aspects of incretin-based therapies PS 47 Glycaemic control and incretin-based therapies PS 46 Clinical outcome of incretin-based therapies PS 45 Basic aspects of incretin-based therapies PS 44 Different aspects of SGLT-2 inhibitors PS 43 SGLT-2 inhibitors: clinical aspects PS 37 Models of obesity and insulin resistance PS 30 Treatment of hyperglycaemia in pregnancy PS 28 The fundamentals of insulin resistance PS 27 Incremental studies on gut hormones PS 24 Pregnancy: in vitro and in vivo studies
PS 23 The ins and outs of carbohydrate metabolism PS 21 Further down the road to human islet failure in type 2 diabetes PS 19 To live and let die: a beta cell perspective PS 17 Islets in type 1 diabetes: new players
PS 14 Prevalence of type 2 diabetes around the world PS 12 Global aspects on the epidemiology of type 2 diabetes PS 11 Markers and phenotypes of glucose traits
PS 10 Islets and antibodies in type 1 diabetes PS 08 Pathophysiology of glucose homeostasis PS 07 Molecular insights into glucose abnormalities PS 04 Global view on diabetes complications PS 03 Micro- and macrovascular complications of diabetes PS 02 Living with chronic diabetes complications OP 48 Insulin secretion in various subgroups OP 47 Thinking about diabetes complications in the brain OP 46 Challenges in delivering diabetes care: new solutions OP 45 Diabetic foot: new developments in wound healing OP 44 Modelling metabolism: lessons from animals OP 39 Gastro-entero pancreatic factors: organoids, mice and men
#Csi miami season 5 episode 3 death pool 100 cho drivers#
OP 38 Triggers and drivers of beta cell failure in type 1 diabetes OP 37 A deep dive into the mechanisms of diabetes OP 36 On the road to human islet failure in type 2 diabetes OP 34 Back to the future: risk markers in diabetes OP 32 Reducing the burden of hypoglycaemia OP 31 Novel aspects of diabetic neuropathy OP 30 Understanding the mechanisms of diabetic kidney disease OP 29 What's new in automated insulin delivery
OP 27 Macrovascular complications and beyond OP 23 Addressing potential new treatments of diabetic kidney disease OP 22 New Treatments for NAFLD: Hope or Hype? OP 21 SGLT-2 inhibitors: at the heart of the matter OP 20 Feeding the pipeline: from drugs to surgery OP 19 Decoding the heritable basis of type 2 diabetes OP 18 Unlocking the potential of digital health OP 16 Signals and networks in beta cell failure OP 15 Pregnancy in diabetes prediction and outcomes OP 13 Diabetic retinopathy: see what's new? OP 11 From diagnostics to the end-stage of diabetic kidney disease OP 08 Charting human beta cell failure in type 1 diabetes OP 07 Smoke on the water: Is BAT still hot? OP 06 Uncomplicating the pathogenesis of diabetes complications in humans OP 05 Glucose-lowering therapies and the liver OP 02 News on the insulin secretion front OP 01 Diabetes complications: new insights from cutting edge epidemiology